Condella Sarah's Form 4/A amendment
AmendedExact Sciences Corp (EXAS) · filed Feb 16, 2022
- Accession no.
- 0001209191-22-010362
- Filed
- Feb 16, 2022
- Trade date
- Jun 11-14, 2021
- Filing delay
- 250 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jun 14, 2021
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $667.5K. It was filed 250 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Condella SarahCIK 0001839989 | Officer (SVP, Human Resources) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2021 | Common Stock | MOption exerciseAcquired | +5,050 | $5.03 | +$25,401.5 | 75,930 | Direct | |
| Jun 11, 2021 | Common Stock | MOption exerciseAcquired | +8,052 | $21.68 | +$174,567.36 | 83,982 | Direct | |
| Jun 14, 2021 | Common Stock | MOption exerciseAcquired | +1,950 | $5.03 | +$9,808.5 | 85,932 | Direct | |
| Jun 14, 2021 | Common Stock | SSaleDisposed | −2,945 | $121.88F2 | −$358,936.6 | 82,987 | Direct | |
| Jun 14, 2021 | Common Stock | SSaleDisposed | −1,470 | $122.78F3 | −$180,486.6 | 81,517 | Direct | |
| Jun 14, 2021 | Common Stock | SSaleDisposed | −885 | $123.58F4 | −$109,368.3 | 80,632 | Direct | |
| Jun 14, 2021 | Common Stock | SSaleDisposed | −150 | $124.42 | −$18,663 | 80,482 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2021 | Common Stock | MOption exerciseDisposed | −5,050 | $5.03 | −$25,401.5 | 5,850 | Direct | |
| Jun 11, 2021 | Common Stock | MOption exerciseDisposed | −8,052 | $21.68 | −$174,567.36 | 21,948 | Direct | |
| Jun 14, 2021 | Common Stock | MOption exerciseDisposed | −1,950 | $5.03 | −$9,808.5 | 3,900 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in February 2021.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.37 to $122.36, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.37 to $123.11, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.23 to $123.80, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
Referenced by the price of 1 transaction in Table I.
- F5
These options vested and became exercisable in full on February 28, 2020.
- F6
These options vested and became exercisable in full on February 23, 2021.